Key Takeaways
- Liquidia (LQDA) shares tumbled 57% following an adverse patent infringement verdict.
- A federal judge in Delaware determined that Yutrepia violates a United Therapeutics patent.
- United Therapeutics (UTHR) shares surged 12% following the favorable ruling.
- Share volume exploded to 22.95 million, approximately 19 times typical levels.
- The company intends to appeal and seek FDA approval for label modifications.
Shares of Liquidia (LQDA) experienced a devastating 57% decline during Wednesday’s trading session, settling at $30.26. The biotech stock edged up 0.13% to $30.30 in after-hours trading.
The precipitous decline came after a Delaware federal court decision determined that Liquidia’s pulmonary treatment Yutrepia violates a critical patent owned by competitor United Therapeutics (UTHR).
The ruling validated two specific claims from United Therapeutics’ intellectual property portfolio as both legitimate and infringed upon. Additional claims presented during litigation were deemed invalid by the court.
The patent in question protects therapeutic methods for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). It specifically covers inhaled treprostinil administered via dry powder formulationsāthe exact delivery mechanism employed by Yutrepia.
Implications for Yutrepia’s Market Future
The judge also rejected Liquidia’s attempt to exclude evidence related to United Therapeutics’ patent ownership rights. The court determined that Liquidia received adequate advance notification and failed to file timely objections.
Liquidia acknowledged it cannot currently quantify the financial impact of this decision. The ultimate cost will depend on appellate outcomes and subsequent legal proceedings.
Potential remedies under consideration range from eliminating the PH-ILD indication from Yutrepia’s approved uses to implementing stringent marketing limitations. United Therapeutics has petitioned for an injunction that would significantly constrain Yutrepia’s commercial distribution.
Both pharmaceutical companies must present proposed final judgments to the court within seven days. A conclusive ruling is anticipated shortly thereafter.
Liquidia CEO Roger Jeffs expressed strong disagreement with the verdict. “We respectfully disagree with the Court’s decision regarding claims 1 and 14 and are fully prepared to pursue all available appellate options,” he stated.
Jeffs indicated that Liquidia will submit a supplemental application to the FDA requesting removal of the PH-ILD indication from Yutrepia’s approved label.
Yutrepia received regulatory clearance in 2025 for treating both pulmonary arterial hypertension and PH-ILD. The PH-ILD approval now faces legal uncertainty.
Analyst Reactions and Market Response
Wall Street analysts offered divergent perspectives on the ruling’s severity. Raymond James analyst Ryan Deschner interpreted the rejected evidence motion as an ominous signal for Liquidia’s overall legal position.
Leerink Partners characterized the outcome as advantageous for United Therapeutics, noting the court validated both patent legitimacy and infringement. RBC Capital’s Lisa Walter suggested the decision creates significant uncertainty regarding Yutrepia’s competitive viability.
United Therapeutics stock rallied 12% to $540.54 on the favorable ruling. The decision strengthens intellectual property protections surrounding its flagship inhaled therapy, Tyvaso.
Liquidia shares fell to their lowest level in approximately four months following the announcement. The decline potentially erases roughly $3.18 billion in shareholder value.
Market activity around the stock intensified dramatically. Daily volume reached 22.95 million shares, representing nearly 19 times the average daily volume of 1.21 million shares.
Liquidia’s Relative Strength Index registered 20.23, entering territory generally viewed as oversold by technical analysts. The stock now trades at approximately 12% of its 52-week price range.
Notwithstanding Wednesday’s sharp decline, Liquidia shares remain 33% higher compared to twelve months ago. The company’s market capitalization stands at $2.71 billion, well below its 52-week peak of $93.61 per share.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
